Showing results (331-340 of 341) with videos related to

Sort By:
Pageof 35
Cancer Treatment and Research Communications|March 9, 2026
A viable human lung cancer tissue collection (LCTC) to accelerate translational researchVirginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, et al.
JAMA|September 10, 2025
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical TrialAlexander B C D Ng, Aqua Asif, Ridhi Agarwal, et al.
The Journal of Cardiovascular Surgery|December 1, 2023
Guidelines on the diagnosis, treatment and management of visceral and renal arteries aneurysms: a joint assessment by the Italian Societies of Vascular and Endovascular Surgery (SICVE) and Medical and Interventional Radiology (SIRM)Carlo Pratesi, Davide Esposito, Romeo Martini, et al.
Journal of Cardiovascular Computed Tomography|March 21, 2021
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patientsFrancesco Giannini, Marco Toselli, Anna Palmisano, et al.
Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumabChiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Cancers|July 9, 2020
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial GroupSanne Nieuwenhuizen, Robbert S Puijk, Bente van den Bemd, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationAndrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, et al.
Radiology|September 28, 2021
Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN InitiativeRobbert S Puijk, Muneeb Ahmed, Andreas Adam, et al.
The Lancet Regional Health. Europe|April 21, 2025
Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trialRemon Korenblik, Sinéad James, Jens Smits, et al.
Pageof 35